Study Focuses on Outpatient CAR T-Cell Therapy in Multiple Myeloma

Taiga Nishihori, MD, senior member in the Blood & Marrow Transplant and Cellular Immunotherapy Department at Moffitt Cancer Center, discusses a study in which investigators evaluated patients with relapsed and/or refractory (R/R) multiple myeloma who were hospitalized and treated with commercial ciltacabtagene autoleucel (cilta-cel; Carvykti) at Moffitt Cancer Center between May 2022 and May 2023.

Patients in the initial group to be evaluated were given lymphodepleting chemotherapy as outpatient, followed by chimeric antigen receptor (CAR) T-cell infusion as inpatient. Patients were also monitored, then discharged to an outpatient immune cell therapy service. The first 30 days post-infusion was the focus of the study.

Transcription:

0:09 | We wanted to look at our experience on treating patients with multiple myeloma who received cilta-cel, which is a CAR T-cell [therapy]. We started looking at this in 2022. Initially, we started doing an outpatient model, which was the beginning of it, and then we changed it to inpatient. The chemotherapy was given, lymphodepletion in particular, and chemotherapy was given as an outpatient; they readmitted patients. But then, we quickly realized that patients who are in the hospital were basically spending a lot of time waiting for toxicity to occur. We changed our approach entirely outpatient. And then we looked at over 20 patients who received those. We also demonstrated that the amount of time they spend in a hospital has been cut down from 11 days to a median of 4 days.

1:11 | We wanted to look at the hospital duration. We also wanted to look at the outcomes of this approach. We have established our system to take care of patients, mostly on the outpatient side. The patients are seen daily in what is called 3 central outpatient areas, and we have managed to conduct this safely as an outpatient.

REFERENCE:

1. Waqar S, Hansen DK, Freeman CL, et al. Evaluation of outpatient administration of ciltacabtagene autoleucel in relapsed/refractory multiple myeloma: single center experience. Presented at: 2024 Transplantation & Cellular Therapy Meetings: February 21-24, 2024; San Antonio, TX. Abstract 532.